Danish health authority triggers reimbursement review for oncology portfolio
The Danish Medicines Agency (Lægemiddelstyrelsen DKMA) initiated a public hearing on 27 March 2026 regarding the Consultation: We are reassessing the reimbursement status of a range of medicines against cancer (Høring: Vi revurderer tilskudsstatus til en række lægemidler mod kræft). This periodic update – which forms part of a systematic review of therapeutic classes – follows a policy where the state seeks to remove automatic subsidies for drugs primarily administered in hospital settings. The measure shifts the burden of proof to manufacturers to justify why these products should remain available via pharmacy prescriptions.
The review covers several Antineoplastic and Immunomodulating Agents. The Reimbursement Committee (Medicintilskudsnævnet) will evaluate whether these products still meet the criteria for general reimbursement. The agency assesses that because cancer treatment largely occurs in hospitals – where drugs are provided free of charge – maintaining automatic pharmacy subsidies is no longer relevant. These data show that the regulator intends to prune the list of products that could be more efficiently managed through the hospital-led ‘free delivery’ list (Liste over vederlagsfri udlevering).
The scope includes medicines also used for conditions such as infertility, endometriosis, and precocious puberty. The DKMA maintains that even these indications typically fall under hospital-based care. If the committee recommends removing general reimbursement, physicians would have to apply for individual reimbursement for each patient. This administrative hurdle typically drives a market shift toward products that remain on the hospital-procured list.
Stakeholders have until 6 May 2026 to submit clinical and economic arguments to the DKMA. The implementation of final decisions will follow a review of all consultation responses. This development creates a period of commercial uncertainty for established brands. Success in maintaining access will depend on providing evidence that pharmacy-based access remains the most clinically appropriate and cost-effective pathway for specific patient groups.
Source: Lægemiddelstyrelsen
Link: Høring: Vi revurderer tilskudsstatus til en række lægemidler mod kræft (Consultation: We are reassessing the reimbursement status of a range of medicines against cancer)
Date: 27 March 2026
